TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean Squeeze Pressure (MSP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distant metastases rate (DMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Acceptance of midazolam administration
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of crying
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Communication skills ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Burnout scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Prevention of fatality from opioid overdose
Endpoint domain: Mortality/survival
Primary endpoint: graft size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Grade IV venous gas embolism incidence
Endpoint domain: Adverse events/effects
Primary endpoint: number of self-reported symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: positive perception of global health status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: lumbar extensor power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction in inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correction of dyslipidemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean knowledge scores of malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of respondents correctly following malaria management guidelines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resident total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resident ranking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma homoarginine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum CTX suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary CTX suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary NTX suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Congruence in adolescent/surrogate preferences for end-of-life care
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Skin Quality Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Self-Esteem Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: First Impressions Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 5-year Overall Survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Range of spine motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall UPDRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Axial subscore
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Axial hypertonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfactory results with their procedure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Increased chances of responding to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV seropositivity rate
Endpoint domain: Mortality/survival
Primary endpoint: amount of medical information identified
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ability to communicate about feasibility of treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Severe reactions to SCIT injections
Endpoint domain: Adverse events/effects
Primary endpoint: Hemoglobin (hb) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum Ferritin (SF) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mitigation of iron-deficiency anemia (IDA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: overall symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of delusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset of pain delay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortisol concentration decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in FEV1 after therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Healing rates of benign gastric ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom severity (daytime and nighttime)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LMA MACex of enflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in postprandial glucose (PPG) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: morning headache reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: orofacial pain intensity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in rhythmic masticatory muscle activity (RMMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0,48 h) of atorvastatin acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) of atorvastatin lactone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0,24 h) of pravastatin lactone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CU traits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in length of Barrett's esophagus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Progression to high grade dysplasia (HGD)
Endpoint domain: Adverse events/effects
Primary endpoint: Average 24-h glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Homeostasis model assessment of β-cell function (HOMA-B)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Duration of convalescence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peroneal motor amplitude postexercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vibratory sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual analog score for pain postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Submaximal functional capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean SF-36 physical function at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: survival to 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Nitrous oxide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric acid output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle taurine content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: systolic and diastolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean daily postprandial glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 1-year relapse-free rate (RFR)
Endpoint domain: Mortality/survival
Primary endpoint: maximum myocardial lactate production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: transcardiac pH differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative peak values of creatine kinase‐MB mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: postoperative peak values of troponin I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Compliance increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Right hip extension ROM improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left hip extension ROM improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trunk flexor muscle performance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant feedback on story content and format
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in parkinsonism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in akathisia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: delta(13)CO(2)/mL values of the (13)C‐urea breath test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean improvement in daily step count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subsequent breast cancer
Endpoint domain: Mortality/survival
Primary endpoint: VAS and i-VAS pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to bowel recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean length of hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Average time of improving in health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood methemoglobin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum IGF‐I concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum IGFBP‐3 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct reading rate of blood slides
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in serum urea concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of patients with at least 50% reduction of SRRC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of pruritus on VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in propofol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bruising
Endpoint domain: Adverse events/effects
Primary endpoint: self-perceived quality of life (QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean FT decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cutaneous manifestations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Histamine-induced flare and itch
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: CoQ levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum types I and III N-terminal procollagen peptide (PINP and PIIINP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein turnover increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ABPI improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: ACD improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mean reepithelialization time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reepithelialization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (Area Under the Curve) after oral treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Helmet use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total and motor composite scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Palatability of the new paediatric valaciclovir formulation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: maximum local skin reactions (LSR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: 7-day physical activity self-report
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment benefit among adherent patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of subclinical shedding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Endobronchial lidocaine dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intravenous fentanyl dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aortic enhancement in first-pass acquisition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Impairment of perceptual priming
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repaired tendon thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strength recovery and functionality
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Treatment compliance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean arterial pressure (MAP)/mean arterial flow (Fmed)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Arterial pulse pressure (APP)/systolic maximum arterial flow (Fmax syst)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Systolic blood pressure (SBP)/R‐R ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Symptom-adjusted and severity-adjusted joint scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of death or recurrent MI
Endpoint domain: Mortality/survival
Primary endpoint: Recurrent MI
Endpoint domain: Mortality/survival
Primary endpoint: mean breathlessness scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative risk of stroke
Endpoint domain: Mortality/survival
Primary endpoint: spontaneous birth <34 weeks
Endpoint domain: Mortality/survival
Primary endpoint: adverse neonatal outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neonatology outcomes
Primary endpoint: Visual Acuity (VA) at week 104
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in sperm concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: odds of response to mailed questionnaires
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical improvement (PANSS total score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in postural hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in postprandial hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in exertion-induced hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: being seizure-free at month 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Median angulation of radius and ulna fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complications (cast saw injury, transient neurological abnormalities)
Endpoint domain: Adverse events/effects
Primary endpoint: VAS scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: MOXFQ scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: VAS score for pain on third day postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to first stool after the operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of analgesics during one week postoperatively
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: procedural success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ease of placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Filtration fraction reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: occurrence of severe sepsis or septic shock
Endpoint domain: Adverse events/effects
Primary endpoint: body mass index change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in NRS for maximum and mean pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: opioid escalation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of deep wound infection
Endpoint domain: Adverse events/effects
Primary endpoint: average fat reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subject satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in Helkimo indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in touch threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma retinol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma BC concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Milk VA concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical remission
Endpoint domain: Physiological/clinical
Primary endpoint: time to colectomy
Endpoint domain: Physiological/clinical
Primary endpoint: Timed Up & Go (TUG) test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: genitourinary symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: skin reactions
Endpoint domain: Adverse events/effects
Primary endpoint: vaginal mucosal reactions
Endpoint domain: Adverse events/effects
Primary endpoint: tissue repair index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dynamic lower limb (LL) angles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spinal angles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surgical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of severe anaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: risk of low birth weight (LBW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating concentrations of CRP, fibrinogen, and IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: requirement for supplemental electrolytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: pulmonary mechanics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: variceal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: variceal radius
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: transmural variceal pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean increase in FEV1 from pre-dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: poor clinical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of haemorrhage on control CT within 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of myocardial infarctions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of reinterventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Gatekeeper Behavior scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decline in HBsAg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decline in Treg proportions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in NKG2C(+) NK cell proportions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Stabilisation on buprenorphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes